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Aim To investigate the influence of tumor necrosis factor 
(TNF) microsatellite polymorphisms on patient survival fol-
lowing hematopoietic stem cell transplantation.
Methods We analyzed TNFa, TNFb, and TNFd microsatel-
lites among 100 patients who underwent allogeneic he-
matopoietic stem cell transplantation from a human leu-
kocyte antigen (HLA)-identical sibling donor at the Internal 
Clinic of the University Hospital Center Zagreb in the pe-
riod 2001-2009. The analysis was performed using poly-
merase chain reaction amplification and electrophoresis 
on a polyacrylamide gel in an automated sequencer.
Results There was no significant difference in patient sur-
vival with respect to the allele length at a given microsat-
ellite. However, a significantly lower survival rate was no-
ticed among patients who were positive for TNFa8 allele 
(P < 0.001) and a significantly higher survival rate among 
those who were positive for TNFa10 allele (P = 0.0220).
Conclusion These results for the first time suggest an in-
fluence of TNFa microsatellite on patient survival following 
HSCT and indicate a need for further studies of this mic-
rosatellite.
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Hematopoietic  stem  cell  transplantation  (HSCT)  is  con-
sidered to be the most effective treatment for numerous 
diseases and disorders of hematological system despite its 
considerable side-effects and treatment-induced mortal-
ity. One of the most common complications of this proce-
dure is acute graft vs host disease (GvHD), which can occur 
even in the cases when transplantation is performed  from 
a human leukocyte antigen (HLA)-identical sibling donor 
and which affects up to 50% of the patients (1). GvHD is a 
consequence of tissue damage and subsequent bacterial 
infiltration due to the conditioning of patients prior to the 
HSCT. The resulting release of the proinflammatory cytok-
ines then triggers the activation of donor’s T cells, which 
in turn leads to tissue damage of target organs and a pos-
sible multi-organ failure. The major role in this, so called 
cytokine storm, which constitutes both the induction and 
effector phase of the GvHD, is played by tumor necrosis 
factor α (TNFα) cytokine (2). The level of TNFα during the 
conditioning period has been associated with the severity 
of the acute GvHD (3).
The role of polymorphisms located within the TNF gene 
cluster region in the etiology of various diseases that have 
shown an association with the HLA system has been ex-
tensively  studied.  A  large  number  of  single  nucleotide 
polymorphisms and 6 microsatellites have been described 
in the TNF region to date. The first five microsatellites are 
referred to as TNFa, TNFb, TNFc, TNFd, and TNFe (4). The 
sixth microsatellite (TNFf) was described later (5). TNFc, 
TNFd, and TNFe are (GA)n repeats, whereas TNFa and TNFf 
are (GT)n and (CA)n repeats, respectively. The only excep-
tion of this dinucleotide repeat motif is the TNFb micro-
satellite, which is composed of mononucleotide tandem 
repeats (G/A)n. The most polymorphic TNF microsatellite is 
TNFa with 14 alleles, while 7 alleles have been reported so 
far for TNFb and TNFd loci each (4). The role of these mic-
rosatellites was implicated in the development of diseases 
such as rheumatoid arthritis, multiple sclerosis, or type 1 di-
abetes (6-8). However, in the transplantation field, the most 
intriguing aspect of these polymorphisms is that, accord-
ing to several studies (9,10), the level of the TNFα secretion 
is influenced by the presence of some alleles at the TNF mi-
crosatellite loci. Taking into account the importance of this 
cytokine in the induction of GvHD, the information about 
the potential of the patient’s immune cells to produce it is 
of great value in the evaluation of risk for GvHD occurrence 
and prediction of HSCT outcome. The analysis of these mi-
crosatellites could therefore be applied in the detection of 
those patients who are at higher risk of developing GvHD 
after HSCT (11).
The aim of this study was to investigate the importance 
of selected TNF microsatellites in the patient survival fol-
lowing HSCT. The choice of the loci included in the anal-
ysis (TNFa, TNFb, and TNFd) was guided by the above 
mentioned study (11), as well as by the level of polymor-
phism detected for a given locus in the Croatian popula-
tion (12).
MateRiaLS and MethodS
The study included 100 patients who were part of the 
transplantation program at the Internal Clinic of the Uni-
versity Hospital Center Zagreb in the period 2001-2009, 
and received the transplant from an HLA-identical sibling 
donor. The criteria for the inclusion of a given patient into 
the study were the type of conditioning (myeloablative 
protocol) and donor (HLA-identical sibling). The following 
patients’ characteristics were noted: age, diagnosis, sex and 
sex-matching with the donor (Table 1). The control group 
consisted of 150 healthy individuals who were analyzed for 
TNF microsatellites in a previous study (12).
DNA was isolated from the peripheral blood using the 
Nucleospin® Blood kit (Macherey-Nagel, Duren, Germa-
ny). All samples were analyzed for three TNF microsatel-
lites (TNFa, TNFb, and TNFd). The analysis was performed 
using polymerase chain reaction (PCR) with specific, flu-
orescently  labeled  primers  according  to  the  protocol 
reported by Udalova (4). The PCR amplification was fol-
lowed by electrophoresis on a 6% polyacrylamide gel in 
an automated sequencer ALFexpress (Amersham Phar-
macia, Uppsala, Sweden). The calculation of the length of 
amplified fragments and allele assignation was performed 
taBLe 1. Characteristics of patients (n = 100) who received the 
transplant from a human leukocyte antigen (hLa)-identical 
sibling donor 
Characteristic no. of patients
age, years, (median, range) 26 (1-53)
diagnosis:
acute myeloid leukemia 28
acute lymphocytic leukemia 25
chronic myeloid leukemia  8
chronic lymphocytic leukemia  2
non-Hodgkin’s lymphoma  7
aplastic anemia 13
myelodysplastic syndrome  5
other 12
Sex, male/female 54/46
Sex matching of patient and donor, 
matched/mismatched
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using the AlleleLocator software (Amersham Pharmacia, 
Uppsala, Sweden). The alleles were designated as TNFa1-
TNFa14, TNFb1-TNFb7, and TNFd1-TNFd7. The names of 
the alleles reflect the number of the basic motif repeats 
within the allele, eg, TNFa6 allele has 6 repeats of the GT 
sequence. TNFa alleles ranged from 97 bp to 123 bp, TNFb 
alleles from 124 bp to 130 bp, and TNFd alleles from 124 
bp to 136 bp.
In order to evaluate the possible influence of the patient’s 
TNF  microsatellite  allele  length  on  the  patient  survival 
following HSCT, the participants were divided into three 
groups: individuals who carried alleles TNFa1-TNFa6 at the 
TNFa locus were included in group 1, those who carried 
alleles TNFa7-TNFa13 were included in group 3, and those 
who carried one short and one long allele were included 
in group 2. The same principle was applied for TNFb and 
TNFd loci with the first three alleles at both loci being clas-
sified as short alleles and the remaining four alleles as long 
alleles.
The allele frequencies were obtained by direct counting. In 
the cases when only one allele was detected, the person 
was considered homozygous for the microsatellite locus 
in question. Data were analyzed in contingency tables by 
Yates χ2 test with 0.050 level of statistical significance, and 
by Fisher exact test when there were fewer than five cas-
es. P value was corrected by multiplication with the num-
ber of detected alleles (Pcorr). Kaplan-Meier analysis was 
performed in the estimation of patient survival. The study 
design was approved by the University Hospital Center’s 
ethics committee and is in accordance with the Helsinki 
Declaration of 1975.
ReSuLtS
There was no significant difference between patients and 
control participants in the distribution of alleles at any of 
the tested microsatellites (Table 2). The survival curve was 
calculated for all patients included in the study (Figure 1). 
The second aim of the study was to evaluate the possible 
influence of TNF microsatellite allele length on patient sur-
vival following HSCT. For this purpose, patients were divid-
ed into three groups and compared according to patient 
survival (Figure 2). No significant difference was found for 
any of the three tested loci (Figure 2).
The final aim of this study was to compare the survival 
of patients according to the presence of an individual al-
lele at the investigated TNF microsatellites. The alleles that 
showed an influence on the patient survival were TNFa8 
and TNFa10 (Figure 3). Patients who carried TNFa8 allele 
taBLe 2. the allele distribution at tumor necrosis factor (tnF) 
loci (tnFa, tnFb, and tnFd) among patients (n = 100) and 
control participants (n = 150)
tnF allele no. (%) of patients no. (%) of controls
TNFa1     3 (1.5)     2 (0.7)
TNFa2   32 (16.0)   50 (16.7)
TNFa3     7 (3.5)     5 (1.7)
TNFa4   13 (6.5)   16 (5.3)
TNFa5   14 (7.0)   25 (8.3)
TNFa6   30 (15.0)   39 (13.0)
TNFa7   13 (6.5)   26 (8.7)
TNFa8     4 (2.0)   -
TNFa9     5 (2.5)   12 (4.0)
TNFa10   51 (25.5)   71 (23.7)
TNFa11   18 (9.0)   34 (11.3)
TNFa12   -   -
TNFa13   10 (5.0)   19 (6.3)
TNFa14   -     1 (0.3)
TNFb1   20 (10.0)   42 (14.0)
TNFb2     1 (0.5)     9 (3.0)
TNFb3   34 (17.0)   39 (13.0)
TNFb4   83 (41.5) 140 (46.7)
TNFb5   57 (28.5)   63 (21.0)
TNFb6   -     3 (1.0)
TNFb7     5 (2.5)     4 (1.3)
TNFd1     4 (2.0)     7 (2.3)
TNFd2   14 (7.0)   17 (5.7)
TNFd3   15 (7.5)     7 (2.3)
TNFd4 107 (53.5) 171 (57.0)
TNFd5   39 (19.5)   64 (21.3)
TNFd6   17 (8.5)   28 (9.3)
TNFd7     4 (2.0)     6 (2.0) FiGuRe 1. total survival of all patients analyzed in the study (n = 100).27 Štingl et al: TNF microsatellite polymorphisms and patient survival following hematopoietic stem cell transplantation
www.cmj.hr
(4.0%) had a significantly lower survival rate than patients 
who did not carry this allele (P < 0.001, Pcorr <0.001). Con-
versely, patients who carried TNFa10 (45.0%) had a signifi-
cantly higher survival rate than patients who did not carry 
this allele (P = 0.022, Pcorr >0.050).
diSCuSSion
This study showed that TNFa microsatellite was a possible 
indicator of patient survival. The study was motivated by 
the work of Pociot et al (13), who demonstrated an asso-
ciation of polymorphisms located in the TNF region with 
the level of TNFα cytokine production. The hypothesis that 
launched further studies, including this one, is that the de-
termination of TNF microsatellite alleles can have a prog-
nostic value in the HSCT outcome and help in the selec-
tion of GvHD treatment and anticytokine therapy.
FiGuRe 2. Patient survival according to tumor necrosis factor (tnF)  micro-
satellites tnFa, tnFb, and tnFd allele length (n = 100). Group i – patients with 
two short alleles; Group ii – patients with one short and one long allele; Group 
iii – patients with two long alleles; short alleles: tnFa1-tnFa6, tnFb1-tnFb3, 
tnFd1-tnFd3; long alleles: tnFa7-tnFa13; tnFb4-tnFb7; tnFd4-tnFd7.
FiGuRe 3. Patient survival according to the presence of tumor necrosis 
factor (tnF) alleles tnFa8 and tnFa10 (n = 100).CLINICAL SCIENCE 28 Croat Med J. 2012;53:24-9
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The first study about the influence of TNF region polymor-
phisms on the outcome of HSCT revealed an association of 
the recipient’s genotype TNFd3/TNFd3 with a higher occur-
rence of GvHD grade II and IV (11). Before that, TNFd3 had 
been shown to correlate with an increased production of 
TNFα (14). The finding that the TNFd3/TNFd3 genotype is 
associated with higher grades of GvHD was based on the 
analysis of only 49 patients, however, this result was later 
confirmed on a larger group (N = 144) of patients (15). A 
more recent study has demonstrated a significantly better 
survival of carriers of TNFd1/d2/d3 genotype than of car-
riers of TNFd3/d3 genotype, and TNFd4 and TNFd5 alleles 
(16). Finally, a Polish study has confirmed the association of 
TNFd3/d3 genotype with more severe forms of GvHD (17). 
Although TNFd3 allele has been emphasized as a risk fac-
tor by a majority of studies conducted so far, it is clear that 
a consensus has not yet been reached about the influence 
of TNF polymorphisms on the occurrence and severity of 
GvHD. This study did not indicate a correlation of the allele 
length at any of the tested loci and survival rates, although 
some  difference  was  observed  for TNFb  and TNFd  loci. 
However, while we could not compare our results for TNFb 
locus with other investigations, patients positive for TNFd1/
d2/d3 genotype did not have a lower survival rate as was 
previously suggested (16). Also, as opposed to the studies 
that have highlighted TNFd3 allele as increased risk factor 
(13,15-17), this study showed an association of TNFa8 allele 
with a lower survival rate after HSCT, while the presence of 
TNFa10 allele correlated with a better prognosis.
In conclusion, this is the first study that indicated an in-
fluence of TNFa microsatellite on patient survival following 
HSCT. The results suggest that a more in-depth analysis of 
this polymorphism should be performed with respect to 
the severity of GvHD as well as other post-transplantation 
complications.
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